Spravato™ is a prescription nasal spray of esketamine, used for treatment-resistant depression (TRD) or Major Depressive Disorder (MDD) with suicidal thoughts.
Spravato ™ cannot be used for pain relief or any other diagnosis and may not be prescribed to minors.
Almost all insurance providers will cover Spravato™ if they deem the treatment the patient to meet the criteria for treatment. We pre-authorize every patient before treatment to ensure they will know the cost ahead of time. Patients with private health insurance can apply for a Janssen’s CarePath Account, which could result in co-pays as little as $10 for each treatment.
Spravato was developed because of the promising scientific results IV Ketamine infusions have shown in treating Major Depressive Disorder. It only contains S-Ketamine, while IV Ketamine infusions include a mixture of S-Ketamine and R-Ketamine. For a more detailed comparison see: Spravato Vs. Ketamine
Please talk to your primary healthcare provider if you have concerns about any of the stated conditions.
Tell your primary healthcare provider about all medical conditions, particularly if you have:
Tell your primary healthcare provider about all the medicines that you take, including supplements. Spravato™ may cause side effects when combined with other medicines.
Central Nervous System (CNS) depressants, psychostimulants, or Monoamine oxidase inhibitors (MAOIs) are of particular concern.